SARS-CoV-2 Spike (SARS-CoV-2 S) Peptide
(3 références)Aperçu rapide pour SARS-CoV-2 Spike (SARS-CoV-2 S) Peptide (ABIN6952485)
Antigène
Origine
Source
Application
-
-
Séquence
- DISGINASVV NIQKEIDRLN EVAKNLNESL IDLQEL
-
Attributs du produit
- 2019-nCov-HR2P
-
Pureté
- ≥ 95 %
-
Ingrédients
- Each vial contains 100 μg of NET peptide.
-
-
SARS-CoV-2 Spike (SARS-CoV-2 S) peptide
SARS-CoV-2 S Reactivité: SARS Coronavirus-2 (SARS-CoV-2) Hôte: Synthetic InhA
SARS-CoV-2 Spike (SARS-CoV-2 S) peptide (Cy5)SARS-CoV-2 S Reactivité: SARS Coronavirus-2 (SARS-CoV-2) Hôte: Synthetic InhA
SARS-CoV-2 Spike (SARS-CoV-2 S) peptide (Cy5)SARS-CoV-2 S Reactivité: SARS Coronavirus-2 (SARS-CoV-2) Hôte: Synthetic InhA
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Powder
-
Stock
- RT,4 °C,-20 °C
-
Stockage commentaire
- Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
-
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." dans: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." dans: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." dans: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." dans: Cellular & molecular immunology, (2020) (PubMed).
-
- SARS-CoV-2 Spike (SARS-CoV-2 S)
-
Classe de substances
- Viral Protein
-
Poids moléculaire
- 4008.50
-
ID gène
- 43740568
-
UniProt
- P0DTC2
Antigène
-
